证券之星消息，截至2025年12月25日收盘，开立医疗(300633)报收于26.75元，上涨0.34%，换手率 0.76%，成交量3.28万手，成交额8763.77万元。 该股主要指标及行业内排名如下： 12月25日的资金流向数据方面，主力资金净流出740.52万元，占总成交额8.45%，游资资金净流入77.14 万元，占总成交额0.88%，散户资金净流入663.39万元，占总成交额7.57%。 近5日资金流向一览见下表： 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 该股最近90天内共有13家 ...

Core Medical: Interventional Left Ventricular Assist System - The National Medical Products Administration (NMPA) has approved the interventional left ventricular assist device and the interventional left ventricular assist catheter pump kit from Shenzhen Core Medical Technology Co., Ltd. [2] - This interventional left ventricular assist system is designed to provide short-term left ventricular support during high-risk percutaneous coronary intervention (PCI) for adult patients with severe coronary artery disease and reduced left ventricular ejection fraction [7]. - The system utilizes self-developed axial magnetic flux multi-drive technology, achieving high flow output and stable performance with a smaller outer diameter, which helps reduce blood damage risk and supports longer clinical use [7][8]. Antai Kangcheng: Tumor Electric Field Therapy Device - The tumor electric field therapy device from Hunan Antai Kangcheng Biotechnology Co., Ltd. has also been approved by the NMPA [2]. - This device consists of a main unit, distribution box, disposable electrode pads, power adapter, lithium-ion battery, and charging dock, and is intended for treating patients aged 22 and older diagnosed with supratentorial glioblastoma [10]. - The device is to be used in conjunction with temozolomide (TMZ) after surgical and radiotherapy treatments [10][11]. Industry Overview - As of now, a total of 391 innovative medical devices have been approved for listing in China [3].

证券之星消息，截至2025年12月24日收盘，开立医疗(300633)报收于26.66元，上涨1.41%，换手率 0.55%，成交量2.37万手，成交额6315.8万元。 12月24日的资金流向数据方面，主力资金净流出606.3万元，占总成交额9.6%，游资资金净流出575.43 万元，占总成交额9.11%，散户资金净流入1181.73万元，占总成交额18.71%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元 ...

每经AI快讯，有投资者在投资者互动平台提问：董秘你好，请问贵司新业务IVUS 导管耗材和硬镜设备 是否导入顺利？ （记者 张明双） 开立医疗（300633.SZ）12月24日在投资者互动平台表示，公司微创外科、心血管介入业务发展顺利， 近两年均取得较高增速。 ...

Group 1 - The core viewpoint of the article is that the company, KaiLi Medical, has experienced significant growth in its minimally invasive surgery and cardiovascular intervention businesses over the past two years [1] Group 2 - The company reported that both business segments have achieved high growth rates [1]

该股主要指标及行业内排名如下： | 指标 | 开立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 113.76亿元 | 107.86亿元 | 27 125 | | 净资产 | 31.19亿元 | 38.83亿元 | 46 125 | | 净利润 | 3351.11万元 | 2.1亿元 | 75 125 | | 市盈率(动) | 254.6 | 78.7 | 88 125 | | 市净率 | 3.65 | 3.73 | 88 125 | | 毛利率 | 60.36% | 51.02% | 50 125 | | 净利率 | 2.3% | 9.59% | 89 125 | | ROE | 1.07% | 0.23% | 85 125 | 证券之星消息，截至2025年12月23日收盘，开立医疗(300633)报收于26.29元，下跌1.35%，换手率 0.54%，成交量2.35万手，成交额6213.08万元。 12月23日的资金流向数据方面，主力资金净流出369.65万元，占总成交额5.95%，游资资金净流出 170.45万元，占总成交额2.74%，散 ...

Core Viewpoint - The official announcement of the sixth batch of high-value medical consumables centralized procurement marks the start of a new phase in the procurement process, focusing on structured competition and stable supply rather than merely price reduction [2][18]. Procurement Scope and Demand Scale - The procurement covers two main categories: drug-coated balloons and urological interventional consumables. The drug-coated balloons are further divided into coronary and peripheral categories, with specific applications detailed for each [6][11]. - The annual demand structure for drug-coated balloons includes: - Coronary drug-coated balloons: 614,778 units - Peripheral arteriovenous fistula drug-coated balloons: 6,884 units - Peripheral upper knee drug-coated balloons: 61,434 units - Peripheral lower knee drug-coated balloons: 7,002 units [10][11]. Grouping Mechanism - The bidding organization will continue to use a unit-based bidding approach, with A/B group logic based on actual demand structure rather than the number of companies. Group A will cater to mainstream clinical needs, while Group B will follow [12][20]. Proposed Selection Rules - Three differentiated proposed selection rules are established for products based on their competitive status, clearly defining price formation and re-bidding space [13][14]. - For products that are selected, they must meet three conditions, establishing a price constraint to avoid price distortion [14][21]. Secondary Bidding Rules - For products that are included but not selected, a secondary bidding opportunity is allowed under specific conditions, maintaining a ceiling on price increases to prevent strategic high pricing [15][21]. - For products not included, stricter conditions apply for re-bidding, indicating a higher difficulty level for selection compared to included products [16][21]. Policy Signals - The procurement process is shifting from a focus on price suppression to a more refined competitive structure, emphasizing sustainable pricing and allowing smaller companies to participate while maintaining overall price discipline [17][18]. Conclusion - The release of the procurement document indicates a transition to a more structured and refined competitive bidding process for high-value medical consumables, where the focus shifts from price advantages to comprehensive evaluations of cost control, product structure, and supply stability [18][19].

开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 证券之星消息，截至2025年12月22日收盘，开立医疗(300633)报收于26.65元，上涨0.26%，换手率 0.48%，成交量2.06万手，成交额5503.53万元。 12月22日的资金流向数据方面，主力资金净流出423.05万元，占总成交额7.69%，游资资金净流入78.72 万元，占总成交额1.43%，散户资金净流入344.32万元，占总成交额6.26%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 以上内容为证券之星据公开信 ...

Core Viewpoint - The event aims to promote the integration of medical and engineering fields, focusing on technological innovation and the deep integration of the medical industry, while providing a platform for collaboration among experts, investors, and innovative enterprises [1]. Event Details - The Future Industry Innovation Seminar on Medical-Engineering Cross-Integration will be held on December 23, 2025, at Tsinghua Science Park Medical-Engineering Cross-Innovation Center [1]. - The event is part of the "2025 Tsinghua Star Annual DEMO DAY" series, gathering clinical experts, investment institutions, industry associations, and innovative companies [1]. - The agenda includes registration, opening remarks, mentor awarding, platform introduction, keynote speeches, and networking opportunities [2][3]. Keynote Topics - Topic 1: "Promoting Results Transformation and Iteration from Technology to Artificial Joints in Total Knee Replacement" presented by a professor from Tsinghua University [3]. - Topic 2: "Exploration of Trends in China's Biopharmaceutical Industry and Investment Development" by the General Manager of a medical fund [3]. - Topic 3: "Medical-Engineering Cross-Validation Platform Supporting Medical Technology Results Transformation" by the head of a validation center [3]. - Topic 4: "Global Medical Technology Innovation Ecosystem" by the editor-in-chief of a medical technology media matrix [3]. Organizing Entities - The event is organized by Tsinghua Holdings, Tsinghua Star, and Tsinghua Science Park Medical-Engineering Cross-Innovation Center, with support from various academic and industry organizations [2].

Investment Rating - The industry investment rating is "Outperform the Market" (预计6个月内，行业指数表现强于市场表现5%以上) [32] Core Insights - The National Healthcare Security Administration issued the "Guidelines for the Establishment of Pricing Projects for Pathological Medical Services (Trial)," which aims to systematically reshape existing pathological pricing projects, focusing on biopsy sampling, sample processing, slice replication, pathological staining, and diagnosis, establishing 28 pricing projects, 3 additional charges, and 2 expansion items. This refined pricing is expected to promote high-quality development in pathology and create new scenarios for the application of artificial intelligence-assisted technologies [4] - The guidelines will standardize the charging for digital pathological slices, solidifying the data foundation for large-scale applications of new scenarios. It includes "providing digital images of pathological slices" as an essential item for various pathological services, reflecting the costs of related resource consumption in pricing [4] - The guidelines also explore suitable forms to respond to the charging demands of artificial intelligence assistance, promoting the early application of AI in the pathology field by including "AI-assisted diagnosis" as an expansion item in the pricing structure [4] - The establishment of separate pricing projects for pathological diagnosis and sample testing emphasizes the value of technical services and supports precise medication guidance [4] Summary by Sections Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipeline layouts, such as Heng Rui Medicine, BeiGene, and China National Pharmaceutical Group. It also highlights companies with significant single-product potential and price revaluation prospects, such as 3SBio, Kaineng Technology, and Qianhong Pharmaceutical. Additionally, it recommends companies leading in cutting-edge technology platform layouts, such as Dongcheng Pharmaceutical, Yuanda Pharmaceutical, and Kelun-Biotech [6] - In the CXO sector, it notes that R&D investment in pharmaceuticals is steadily increasing, and the innovation environment is expected to improve, suggesting attention to companies like WuXi AppTec, WuXi Biologics, and Boteng Co. [6] - For upstream companies, it indicates that quality enterprises are entering a harvest period with overseas layouts, recommending attention to Aopumai, Baipusais, and Baiyao [6] - In the medical device sector, it mentions that ongoing procurement will continue to advance, with equipment companies gradually digesting channel inventory, suggesting attention to Mindray Medical, United Imaging, and Kaili Medical [6] Industry News - The report highlights several key developments in the industry, including Takeda's TYK2 drug achieving positive results in Phase III studies, Baiyatai's anti-VEGF monoclonal antibody application for market approval, Sanofi's innovative therapy for hypertrophic cardiomyopathy receiving domestic approval, and Enhertu (Trastuzumab Deruxtecan) gaining FDA approval for a new indication [8][12][15][16]